INDUSTRY PHARMACOGENOMICS WORKING GROUP
Introduction to I-PWG and our intent for the workshop
In this introduction, we will describe I-PWG, our composition, mission, and goals. We will describe pharmacogenomics and its importance in drug development, activity within the industry to facilitate the study of pharmacogenomics and the modalities that we leverage to contribute to the development of precision medicines.
Moderator: Michelle Penny, Senior Director, Head of Computational Biology and Genomics
Talk 1: Optimizing Pharmacogenomics Sampling in Clinical Trials: Current Practices for collecting DNA
Hear about current solutions within industry, best practices, and challenges to obtaining PGx populations that are representative of the global clinical trial population.
Presenter: Anita Nelsen, Head of Genomic Medicine, PAREXEL International
Talk 2: NGS and its evolving application in pharmacogenomics
Learn how companies are utilizing NGS to inform the discovery and development of safe and effective medicine. Data from an I-PWG survey on NGS practices will be shared.
Presenters: Charles Paulding, Director Pharmacogenomics, Regeneron Pharmaceuticals, Inc. and Denit Oz Levi, Sequencing Analysis & Bioinformatics Expert, Personalized & Predictive Medicine and Big Data Analytics, Teva
Talk 3: Closing the knowledge gap:
Pharmacogenomics education and resources for the patient, site staff and ethics committees
This presentation will highlight the need for pharmacogenomics education and describe some of the resources available through I-PWG.
Presenter: Sandra Prucka, Innovation Lead, Clinical Innovation, Eli Lilly and Company
Panel Discussion- Hot topics
Anita Nelsen, Sr. Dir and Head, Genomic Medicine, PAREXEL International GmbH
Sandra Prucka, Director of Genetic Counseling Clinical Services, Indiana University School of Medicine